MedPath
FDA Approval

COLESTIPOL HYDROCHLORIDE

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Effective Date
December 30, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Colestipol(5 g in 1 1)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Amneal Pharmaceuticals of New York, LLC

Amneal Pharmaceuticals of New York LLC

123797875

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

COLESTIPOL HYDROCHLORIDE

Product Details

NDC Product Code
0115-5212
Application Number
ANDA077277
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
December 30, 2023
Code: X7D10K905GClass: ACTIBQuantity: 5 g in 1 1
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4Class: IACT

COLESTIPOL HYDROCHLORIDE

Product Details

NDC Product Code
0115-5213
Application Number
ANDA077277
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
December 30, 2023
Code: X7D10K905GClass: ACTIBQuantity: 5 g in 1 1
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4Class: IACT
© Copyright 2025. All Rights Reserved by MedPath